Intrahepatic Cholangiocarcinoma: State of the Art of FGFR Inhibitors

Objective: Intrahepatic cholangiocarcinoma (iCCA), the second most common type of primary liver tumor, has an increasing incidence in the past few decades. iCCA is highly malignant, with a 5-year survival rate of approximately 5-10%. Surgical resection is usually the prescribed treatment for patients with early stage iCCA; however, patients are usually in an advanced stage iCCA upon diagnosis. Currently, targeted therapy combined with chemotherapy and other comprehensive treatment measures have been mainly adopted as palliative treatment measures. As a common candidate of targeted therapy, FGFR inhibitors have demonstrated their unique advantages in clinical trials. At present, the prospect of FGFR targeted therapy is encouraging. The landscape of FGFR inhibitors in iCCA is needed to be showed urgently. Methods: We searched relative reports of clinical trials on FGFR inhibitors in PubMed as well as Web of Science. We also concluded other available clinical trials of FGFR inhibitors (Data were collected from clinicaltrials.gov ). Results: Several relatively effective targeted drugs are being used in clinical trials. Some preliminary results indicate the outlook of targeted therapy such as BGJ398, TASI20, and HSP90 inhibitors. Conclusions: In summary, FGFR targeted therapy has broad prospects for the treatment of iCCA.

Automated summary

This study discusses the application prospects of targeted therapy in iCCA, with FGFR inhibitors showing unique advantages in clinical trials. Results indicate that several effective targeted drugs are currently being used in clinical trials, with promising treatment methods including BGJ398, TASI20, and HSP90 inhibitors.